دورية أكاديمية
أعرض في EDS

Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023.

التفاصيل البيبلوغرافية
العنوان: Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023.
المؤلفون: Matera MG; Unit of Pharmacology, Department of Experimental Medicine, School of Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy., Calzetta L; Unit of Respiratory Disease and Lung Function, Department of Medicine and Surgery, University of Parma, Parma, Italy., Rogliani P; Unit of Respiratory Medicine, Department Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy., Hanania N; Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA., Cazzola M; Unit of Respiratory Medicine, Department Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it.
المصدر: Lung [Lung] 2024 Apr; Vol. 202 (2), pp. 119-125. Date of Electronic Publication: 2024 Feb 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: United States NLM ID: 7701875 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1750 (Electronic) Linking ISSN: 03412040 NLM ISO Abbreviation: Lung Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer Verlag
Original Publication: Heidelberg, Springer International.
مواضيع طبية MeSH: Pulmonary Disease, Chronic Obstructive*/drug therapy , Pulmonary Disease, Chronic Obstructive*/epidemiology , Pulmonary Disease, Chronic Obstructive*/chemically induced , Cardiovascular Diseases*/chemically induced , Cardiovascular Diseases*/epidemiology, United States/epidemiology ; Humans ; Tiotropium Bromide/adverse effects ; Glycopyrrolate/adverse effects ; Retrospective Studies ; United States Food and Drug Administration ; Adrenergic beta-2 Receptor Agonists ; Drug Combinations ; Muscarinic Antagonists/therapeutic use ; Bronchodilator Agents ; Receptors, Muscarinic/therapeutic use ; Administration, Inhalation
مستخلص: Purpose: This study aimed to examine reports of cardiovascular adverse events (CV AEs) observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and umeclidinium alone or in combination with a LABA and, in the context of triple therapy, with the addition of an ICS, and submitted to the food and drug administration adverse event reporting system (FAERS).
Methods: A retrospective disproportionality analysis was conducted utilizing CV AE reports submitted to the FAERS from January 2020 to 30 September 2023. Disproportionality was measured by calculating the reporting odds ratio.
Results: Compared with ipratropium, tiotropium was associated with fewer reports of CV AEs. Compared with tiotropium, other LAMAs were more likely to be associated with reports of CV AEs. Combinations of glycopyrronium with indacaterol or formoterol and umeclidinium with vilanterol significantly reduced reports of CV AEs compared with the respective LAMA. The addition of an ICS to these combinations further reduced the risk of CV AE reports.
Conclusion: Our study suggests that inhaled LAMAs are not free from cardiac AE risks. This risk may be more evident when the newer LAMAs are used, but it is generally significantly reduced when COPD patients are treated with dual bronchodilators or triple therapy. However, these results do not prove that LAMAs cause CV AEs, as FAERS data alone are not indicative of a drug's safety profile. Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue.
(© 2024. The Author(s).)
References: Physiol Genomics. 2018 Jan 1;50(1):1-9. (PMID: 29093194)
Chronic Obstr Pulm Dis. 2023 Jul 26;10(3):317-327. (PMID: 37289196)
Pulm Pharmacol Ther. 2012 Feb;25(1):19-26. (PMID: 22051450)
Pulm Pharmacol Ther. 2013 Jun;26(3):307-17. (PMID: 23274274)
JAMA. 2019 May 7;321(17):1693-1701. (PMID: 31063575)
Lancet Respir Med. 2018 May;6(5):368-378. (PMID: 29477448)
Ther Adv Chronic Dis. 2017 Apr;8(4-5):81-91. (PMID: 28491268)
J Immunother Cancer. 2019 Nov 6;7(1):286. (PMID: 31694698)
Lancet Respir Med. 2015 Aug;3(8):593-5. (PMID: 26208993)
Br J Clin Pharmacol. 2022 Aug;88(8):3657-3673. (PMID: 35514240)
Am J Respir Crit Care Med. 2019 May 1;199(9):1086-1096. (PMID: 30641027)
BMC Pulm Med. 2014 Jan 17;14:4. (PMID: 24438744)
PLoS One. 2013 Oct 29;8(10):e76973. (PMID: 24204714)
Int J Chron Obstruct Pulmon Dis. 2018 Jun 12;13:1873-1888. (PMID: 29928118)
Chest. 2010 Jan;137(1):13-9. (PMID: 19363211)
Int J Chron Obstruct Pulmon Dis. 2022 Aug 02;17:1715-1733. (PMID: 35941901)
BMJ. 2013 Feb 22;346:f1185. (PMID: 23435603)
Drug Saf. 2016 Jun;39(6):501-8. (PMID: 26924197)
Thorax. 2013 Jan;68(1):114-6. (PMID: 22764216)
Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519-23. (PMID: 15317031)
Pulm Pharmacol Ther. 2014 Aug;28(2):114-21. (PMID: 24928173)
Int J Cardiol. 2014 Dec 15;177(2):646-9. (PMID: 25449471)
Open Respir Med J. 2022 Feb 08;16:e187430642112240. (PMID: 37273944)
JAMA Intern Med. 2013 Jul 8;173(13):1175-85. (PMID: 23689820)
Respir Res. 2014 Jul 11;15:78. (PMID: 25015176)
Chest. 2016 May;149(5):1181-96. (PMID: 26923629)
Expert Opin Emerg Drugs. 2020 Jun;25(2):123-130. (PMID: 32312134)
Toxicol Appl Pharmacol. 2015 Aug 15;287(1):9-16. (PMID: 26026369)
J Investig Med. 2021 Dec;69(8):1391-1398. (PMID: 34362778)
Int J Chron Obstruct Pulmon Dis. 2012;7:729-41. (PMID: 23118536)
J Pharmacol Exp Ther. 2017 Mar;360(3):409-416. (PMID: 28035008)
Ther Adv Drug Saf. 2017 Jan;8(1):17-30. (PMID: 28203364)
Drugs. 2017 May;77(7):721-732. (PMID: 28349353)
Respir Med. 2021 Aug-Sep;185:106461. (PMID: 34116329)
J Pharmacol Exp Ther. 2013 May;345(2):260-70. (PMID: 23435542)
Pulm Ther. 2022 Mar;8(1):57-74. (PMID: 35015270)
J Pharmacol Exp Ther. 2009 Nov;331(2):740-51. (PMID: 19710368)
Drug Saf. 2020 May;43(5):479-487. (PMID: 32008183)
Curr Drug Targets. 2013 Mar;14(3):372-7. (PMID: 23317008)
Adv Ther. 2023 Feb;40(2):445-459. (PMID: 36350532)
PLoS One. 2018 Apr 18;13(4):e0193798. (PMID: 29668674)
فهرسة مساهمة: Keywords: Cardiovascular adverse events; Dual bronchodilation; FAERS; LAMAs; Triple therapy
المشرفين على المادة: XX112XZP0J (Tiotropium Bromide)
V92SO9WP2I (Glycopyrrolate)
0 (Adrenergic beta-2 Receptor Agonists)
0 (Drug Combinations)
0 (Muscarinic Antagonists)
0 (Bronchodilator Agents)
0 (Receptors, Muscarinic)
تواريخ الأحداث: Date Created: 20240206 Date Completed: 20240415 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11009752
DOI: 10.1007/s00408-024-00677-3
PMID: 38321329
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1750
DOI:10.1007/s00408-024-00677-3